INVIVO THERAPEUTICS HLDGS CO's ticker is NVIV and the CUSIP is 46186M209. A total of 64 filers reported holding INVIVO THERAPEUTICS HLDGS CO in Q1 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $463,000 | -24.8% | 866,190 | +8.4% | 0.00% | – |
| Q4 2017 | $616,000 | -48.7% | 799,307 | -1.8% | 0.00% | – |
| Q3 2017 | $1,201,000 | -52.0% | 813,992 | -12.2% | 0.00% | – |
| Q2 2017 | $2,503,000 | -45.0% | 926,766 | -17.6% | 0.00% | – |
| Q1 2017 | $4,555,000 | -4.2% | 1,124,628 | -0.7% | 0.00% | – |
| Q4 2016 | $4,757,000 | -36.3% | 1,132,604 | +3.2% | 0.00% | – |
| Q3 2016 | $7,462,000 | +23.3% | 1,097,343 | +4.8% | 0.00% | – |
| Q2 2016 | $6,050,000 | -11.7% | 1,046,757 | +6.6% | 0.00% | – |
| Q1 2016 | $6,854,000 | +5.6% | 981,951 | +8.9% | 0.00% | – |
| Q4 2015 | $6,490,000 | -57.1% | 901,468 | -48.7% | 0.00% | -100.0% |
| Q3 2015 | $15,140,000 | +32.2% | 1,756,506 | +147.6% | 0.00% | 0.0% |
| Q2 2015 | $11,455,000 | – | 709,285 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IMS Capital Management | 246,966 | $1,778,000 | 2.19% |
| WELCH & FORBES LLC | 902,286 | $6,496,000 | 0.21% |
| Alambic Investment Management, L.P. | 25,100 | $181,000 | 0.11% |
| EMERSON INVESTMENT MANAGEMENT, LLC | 74,175 | $534,000 | 0.10% |
| Hayek Kallen Investment Management | 10,965 | $79,000 | 0.06% |
| Yellowstone Partners, LLC | 10,045 | $72,000 | 0.03% |
| Ausdal Financial Partners, Inc. | 7,750 | $56,000 | 0.03% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 29,647 | $213,000 | 0.03% |
| GROUP ONE TRADING, L.P. | 61,856 | $445,000 | 0.01% |
| Cambridge Investment Research Advisors, Inc. | 10,500 | $76,000 | 0.00% |